236 related articles for article (PubMed ID: 22895066)
1. Antagonism between curcumin and the topoisomerase II inhibitor etoposide: a study of DNA damage, cell cycle regulation and death pathways.
Saleh EM; El-awady RA; Eissa NA; Abdel-Rahman WM
Cancer Biol Ther; 2012 Sep; 13(11):1058-71. PubMed ID: 22895066
[TBL] [Abstract][Full Text] [Related]
2. The influence of curcumin on the action of etoposide in a rat acute myeloid leukemia cell line.
Papiez MA
Folia Med Cracov; 2013; 53(2):61-72. PubMed ID: 24858458
[TBL] [Abstract][Full Text] [Related]
3. Co-delivery of etoposide and curcumin by lipid nanoparticulate drug delivery system for the treatment of gastric tumors.
Jiang H; Geng D; Liu H; Li Z; Cao J
Drug Deliv; 2016 Nov; 23(9):3665-3673. PubMed ID: 27749102
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of etoposide and temozolomide cytotoxicity by curcumin and turmeric force™ in brain tumor cell lines.
Ramachandran C; Nair SM; Escalon E; Melnick SJ
J Complement Integr Med; 2012 Aug; 9():Article 20. PubMed ID: 22944718
[TBL] [Abstract][Full Text] [Related]
5. Curcumin induces DNA damage and caffeine-insensitive cell cycle arrest in colorectal carcinoma HCT116 cells.
Lu JJ; Cai YJ; Ding J
Mol Cell Biochem; 2011 Aug; 354(1-2):247-52. PubMed ID: 21526346
[TBL] [Abstract][Full Text] [Related]
6. Quinacrine and curcumin synergistically increased the breast cancer stem cells death by inhibiting ABCG2 and modulating DNA damage repair pathway.
Nayak D; Tripathi N; Kathuria D; Siddharth S; Nayak A; Bharatam PV; Kundu C
Int J Biochem Cell Biol; 2020 Feb; 119():105682. PubMed ID: 31877386
[TBL] [Abstract][Full Text] [Related]
7. Loss of histone H2AX increases sensitivity of immortalized mouse fibroblasts to the topoisomerase II inhibitor etoposide.
Donà F; Prosperi E; Savio M; Coppa T; Scovassi AI; Mondello C
Int J Oncol; 2008 Sep; 33(3):613-21. PubMed ID: 18695893
[TBL] [Abstract][Full Text] [Related]
8. Nanoemulsion based concomitant delivery of curcumin and etoposide: impact on cross talk between prostate cancer cells and osteoblast during metastasis.
Shukla P; Mathur V; Kumar A; Khedgikar V; Teja VB; Chaudhary D; Kushwaha P; Bora HK; Konwar R; Trivedi R; Mishra PR
J Biomed Nanotechnol; 2014 Nov; 10(11):3381-91. PubMed ID: 26000396
[TBL] [Abstract][Full Text] [Related]
9. Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage.
Schonn I; Hennesen J; Dartsch DC
Apoptosis; 2010 Feb; 15(2):162-72. PubMed ID: 20041303
[TBL] [Abstract][Full Text] [Related]
10. STK295900, a dual inhibitor of topoisomerase 1 and 2, induces G(2) arrest in the absence of DNA damage.
Kim SO; Sakchaisri K; Thimmegowda NR; Soung NK; Jang JH; Kim YS; Lee KS; Kwon YT; Asami Y; Ahn JS; Erikson RL; Kim BY
PLoS One; 2013; 8(1):e53908. PubMed ID: 23349762
[TBL] [Abstract][Full Text] [Related]
11. Etoposide induces G2/M arrest and apoptosis in neural progenitor cells via DNA damage and an ATM/p53-related pathway.
Nam C; Doi K; Nakayama H
Histol Histopathol; 2010 Apr; 25(4):485-93. PubMed ID: 20183801
[TBL] [Abstract][Full Text] [Related]
12. Induction of cell cycle arrest by GL331 via triggering an ATM-dependent DNA damage response in HepG2 cells.
Wang YJ; Chen XG; Xiao ZY; Liu GT; Sun H
J Asian Nat Prod Res; 2012; 14(7):657-64. PubMed ID: 22583615
[TBL] [Abstract][Full Text] [Related]
13. Induction of ATM activation, histone H2AX phosphorylation and apoptosis by etoposide: relation to cell cycle phase.
Tanaka T; Halicka HD; Traganos F; Seiter K; Darzynkiewicz Z
Cell Cycle; 2007 Feb; 6(3):371-6. PubMed ID: 17297310
[TBL] [Abstract][Full Text] [Related]
14. Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells.
Smith PJ; Souès S; Gottlieb T; Falk SJ; Watson JV; Osborne RJ; Bleehen NM
Br J Cancer; 1994 Nov; 70(5):914-21. PubMed ID: 7947097
[TBL] [Abstract][Full Text] [Related]
15. Etoposide Induces Necrosis Through p53-Mediated Antiapoptosis in Human Kidney Proximal Tubule Cells.
Kwon HK; Shin HJ; Lee JH; Park SH; Kwon MC; Panneerselvam S; Lee CG; Kim SG; Kim JH; Choi S
Toxicol Sci; 2015 Nov; 148(1):204-19. PubMed ID: 26259609
[TBL] [Abstract][Full Text] [Related]
16. WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Christmann M; Tomicic MT; Gestrich C; Roos WP; Bohr VA; Kaina B
DNA Repair (Amst); 2008 Dec; 7(12):1999-2009. PubMed ID: 18805512
[TBL] [Abstract][Full Text] [Related]
17. Chemo-sensitisation of HeLa cells to etoposide by a benzoxazine in the absence of DNA-PK inhibition.
Fitzgibbon C; Ihmaid S; Al-Rawi J; Meehan-Andrews T; Bradley C
Invest New Drugs; 2013 Dec; 31(6):1466-75. PubMed ID: 24057508
[TBL] [Abstract][Full Text] [Related]
18. G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status.
Agarwal P; Jackson SP
Cancer Lett; 2016 Oct; 380(2):467-475. PubMed ID: 27431310
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
Zhao Y; Thomas HD; Batey MA; Cowell IG; Richardson CJ; Griffin RJ; Calvert AH; Newell DR; Smith GC; Curtin NJ
Cancer Res; 2006 May; 66(10):5354-62. PubMed ID: 16707462
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint kinase‑1 inhibition and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologous recombination DNA damage repair.
Fan Z; Luo H; Zhou J; Wang F; Zhang W; Wang J; Li S; Lai Q; Xu Y; Wang G; Liang A; Xu J
Oncol Rep; 2020 Nov; 44(5):2152-2164. PubMed ID: 32901871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
